Royalty Pharma (NASDAQ:RPRX) EVP Marshall Urist Sells 13,684 Shares

Royalty Pharma PLC (NASDAQ:RPRX) EVP Marshall Urist sold 13,684 shares of the business’s stock in a transaction on Thursday, May 14th. The stock was sold at an average price of $53.06, for a total transaction of $726,073.04. Following the transaction, the executive vice president owned 31,881 shares in the company, valued at approximately $1,691,605.86. The trade was a 30.03% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Royalty Pharma Price Performance

Shares of RPRX opened at $52.85 on Friday. The company has a current ratio of 2.66, a quick ratio of 2.66 and a debt-to-equity ratio of 0.86. The company’s fifty day simple moving average is $48.31 and its 200 day simple moving average is $43.35. Royalty Pharma PLC has a 1-year low of $32.15 and a 1-year high of $53.47. The company has a market cap of $30.43 billion, a price-to-earnings ratio of 35.95, a PEG ratio of 1.47 and a beta of 0.40.

Royalty Pharma (NASDAQ:RPRX) last released its quarterly earnings data on Wednesday, May 6th. The biopharmaceutical company reported $1.30 EPS for the quarter, topping analysts’ consensus estimates of $1.22 by $0.08. Royalty Pharma had a net margin of 33.88% and a return on equity of 29.25%. The firm had revenue of $631.00 million during the quarter, compared to analysts’ expectations of $881.69 million. On average, research analysts forecast that Royalty Pharma PLC will post 5.05 earnings per share for the current fiscal year.

Royalty Pharma Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, June 10th. Shareholders of record on Friday, May 15th will be given a dividend of $0.235 per share. This represents a $0.94 dividend on an annualized basis and a yield of 1.8%. The ex-dividend date of this dividend is Friday, May 15th. Royalty Pharma’s payout ratio is 63.95%.

Analysts Set New Price Targets

A number of equities analysts have commented on RPRX shares. Weiss Ratings raised shares of Royalty Pharma from a “buy (b-)” rating to a “buy (b)” rating in a research report on Friday, May 1st. Wall Street Zen raised shares of Royalty Pharma from a “buy” rating to a “strong-buy” rating in a research report on Saturday, May 9th. TD Cowen reaffirmed a “buy” rating on shares of Royalty Pharma in a research report on Friday, February 27th. Morgan Stanley lifted their price objective on shares of Royalty Pharma from $61.00 to $63.00 and gave the stock an “overweight” rating in a research report on Friday, April 10th. Finally, Citigroup boosted their target price on shares of Royalty Pharma from $50.00 to $66.00 and gave the company a “buy” rating in a research report on Thursday, May 7th. Seven equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $53.71.

Institutional Investors Weigh In On Royalty Pharma

A number of institutional investors have recently modified their holdings of the business. ABS Direct Equity Fund LLC bought a new stake in shares of Royalty Pharma in the first quarter valued at about $181,000. Gateway Wealth Partners LLC acquired a new position in Royalty Pharma in the first quarter valued at about $565,000. OMERS ADMINISTRATION Corp raised its stake in Royalty Pharma by 14.0% in the first quarter. OMERS ADMINISTRATION Corp now owns 79,307 shares of the biopharmaceutical company’s stock valued at $3,804,000 after purchasing an additional 9,712 shares in the last quarter. Lombard Odier Asset Management Switzerland SA acquired a new position in Royalty Pharma in the first quarter valued at about $342,000. Finally, Dorsey Asset Management LLC raised its stake in Royalty Pharma by 0.8% in the first quarter. Dorsey Asset Management LLC now owns 2,276,570 shares of the biopharmaceutical company’s stock valued at $109,207,000 after purchasing an additional 17,101 shares in the last quarter. Institutional investors own 54.35% of the company’s stock.

Royalty Pharma Company Profile

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company’s transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.